ArticleBreast cancer : basic and clinical research2026
CK8/18 and Claudin Profile of Female Breast Cancers from Botswana.
Article in Breast cancer : basic and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Globally, breast cancer mortality is rising particularly in transitioning countries where it is exacerbated by late diagnosis and poor diagnostic infrastructure. The dearth of data on the biology of breast tumours from under-studied populations compromise management of breast cancer patients resulting in poor patient outcomes. We conducted a study to determine the prevalence and impact of Claudin-low and CK8/18 in the Botswana female breast cancer cohort. Design: This laboratory experimentally retrospective cross-sectional study was carried out on archived formalin-fixed paraffin embedded (FFPE) tissue obtained from mastectomy specimens. Objectives: To determine the protein expression of CK8/18 and Claudin-3, Claudin-4 and Claudin-7 on breast mastectomies from Botswana female breast cancer cohort. Methods: CK8/18, Claudin 3, Claudin 4 and Claudin 7 were Immunohistochemical determined on 125 previously molecular classified Botswana female mastectomies. Statistical software STATA and SPSS were used to determine the relationship between CK8/18 & Claudin expression, clinicopathological variables, breast cancer molecular subtypes, CK5/6 and EGFR. Results: The prevalence of Claudin-low tumours in our cohort was 22% (27/125) had a significant relationship with histological subtype, p=0.002. Claudin 3 and Claudin 4 were highly expressed in 54% (67/125) and 53% (66/125) of breast tumours respectively. Claudin 3 and claudin 4 significantly correlated with molecular breast cancer subtypes, p= 0.001. Claudin 7 was expressed in 47% (59/125) of all breast tumours and had a significant relationship with CK5/6, p=0.029. CK8/18 was highly expressed by 64% (80/125) of mastectomies and correlates with; Tumour grade (p= 0.005) and breast cancer molecular subtypes (p=0.002). Conclusion: Diagnostic stratification of breast tumours should include Claudin-low tumours as they respond differently to therapy when compared to the intrinsic breast cancer molecular subtypes. There is also a significant CK8/18 signaling that warrants deployment of anti-CK8/18 antagonists where ER is poorly expressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.